1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Huntington's disease (HD) (Huntington's chorea, Huntington disease)
1.2 OMIM# of the disease 143100.
1.3 Name of the analysed genes or DNA/chromosome segments HTT.
OMIM# of the gene(s)

143100.
1.5 Mutational spectrum CAG repeat expansion; for polymorphisms see NCBI accession number NM_002111.6. There are SNPs but no other diseaserelevant variations-see: http://www.ncbi.nlm.nih.gov/projects /SNP/ snp_ref.cgi?showRare=on&chooseRs=coding&go=Go&locusId=3064.
Analytical methods
PCR.
Analytical validation
Parallel analysis of negative and positive controls.
1.8 Estimated frequency of the disease 4-10/100.000 with regional variations within ethnic groups, possibly due to a different genetic background. 1 Recently, it has been suggested that improved clinical and molecular diagnosis of cases, an aging population, and increased general knowledge of the disease has lead to even higher prevalence estimates in Caucasian populations. 2 
Diagnostic setting
Invasive prenatal DNA diagnosis is restricted by law in several countries, such as Germany. Pre-implantation diagnosis is technically possible, and it is currently performed, eg, in North America. In several countries, however, PID is restricted by law. Enactment of respective legislation is pending in several other countries. 
TEST CHARACTERISTICS
Negative C D Positive predictive value: Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Nearly 100%. Using PCR as an analytical method, there is the possibility of a false negative result in cases with a very large CAG repeat expansion. Therefore, labs might put a disclaimer on results where both repeat numbers appear to be the same, indicating that this testing method could rarely miss a very large expansion. 3 
Analytical specificity (proportion of negative tests if the genotype is not present)
Nearly 100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
Nearly 100% if family history is informative and symptoms are typical of HD. Notably, however, in some studies over one-quarter of HD patients have a negative family history. In the most comprehensive study to date, up to B7.8% of patients were determined to be new mutations. 4 2. If the test result is negative (please describe) A negative test result has potential impact on family planning and lifestyle, eg, on the choice of education alternatives, professions, career planning etc.
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
The choice to not pursue genetic testing by an at-risk individual will result in a continuation of the 50% risk state, leading to uncertainty and potential impact on family planning and lifestyle, for example, on the choice of education alternatives, professions, career planning etc.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.9 'C' was marked) 
Prenatal diagnosis
(To be answered if in 1.9 'D' was marked) 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Yes, but invasive prenatal DNA diagnosis is restricted by law in several countries, such as Germany. Pre-implantation diagnosis is technically possible, and it is currently performed, for example, in North America. In several countries, however, PID is restricted by law. Enactment of respective legislation is pending in several other countries.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
In both, individuals with negative results (potentially due to guilt feelings) or positive results concerning the mutation in the HTT gene, the diagnosis can lead to depression and to serious consequences. Thus, detailed counselling, sufficient time to consider all the potential consequences and psychotherapeutic accompany are necessary as recommended in the predictive testing guidelines. 9 
